New hope for vasculitis patients: rituximab may outperform standard therapy

This study tested whether rituximab, a targeted antibody therapy, is more effective than the standard drug azathioprine at preventing major relapses in people with ANCA-associated vasculitis (Wegener's granulomatosis or microscopic polyangiitis). 117 adults who had already achieved remission were randomly assigned to receive either rituximab or azathioprine for 18 months, then followed for 10 more months. The main goal was to see which group had fewer severe flare-ups.